Stock Market Plummet and Alnylam Pharmaceuticals Good News Today, the stock market is plummeting. In fact, most stocks have been falling since early morning. The reason has nothing to do with the company’s activities. The best companies with the best science and scientists are sinking into the bottom of the deepest ocean today. Even though the Stock Market is surrounded by negativity, we will still …

Wave Life Sciences On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. FORWARD-53 Trial demonstrates sustained and industry-leading exon . . . This content is for paid subscribers. Please click here to subscribe or here to log …

BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

PTC Therapeutics Inc On March 20, 2025, PTC Therapeutics, Inc. (PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU . . . This content is for paid …

Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to . . . This content is for paid subscribers. Please click here to subscribe or …

Pyxis Oncology in the NEWS Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update On March 18, 2025, Pyxis Oncology (PYXS) - a clinical-stage firm developing next-generation therapeutics for difficult-to-treat cancers, reported financial results for the year and quarter ending December 31, 2024, and provided a business update. From Pyxis Oncology Lara . . . This content is for paid …

Altimmune  Altimmune (ALT) stock soared last Friday after speculation of a takeover by three large companies.  The speculation died today. Nevertheless, other news about this firm could be important, especially from  Altimmune itself. The firm announced that it will assess the potential of GLP . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

With a bad market and a lot of talk about recession and shutting down the Government, with most stocks tanking, in the middle of this chaos some biotech companies, that we selected for investment, have beaten the bad news and moved up, instead of sinking to the bottom of an uneasy ocean. These stocks closed today at: Stock Symbol Price Change

AstraZeneca AstraZeneca (AZN) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (

ARS Pharmaceuticals SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE), ARS Pharmaceuticals (SPRY) announced that the U.S. FDA has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergy reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). This approval represents the first significant innovation in epinephrine delivery for …

Moderna On February 28, 2025, Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Jazz Pharmaceuticals to Acquire Chimerix Today, March 5, 2025, Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

AstraZeneca and Daiichi Sankyo AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) (trastuzumab deruxtecan) has been recommended for approval in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Sanofi New Data Paris, February 28, 2025, Sanofi (SNY) will present 26 abstracts, including one late-breaking presentation and five additional oral presentations, on approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, FL, US, from March 7 to 11 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Cassava Sciences in the NEWS  Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent (US 12,186,3071) for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex (TSC). Simufilam is Cassava . . . This content is …

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – …

Verona Pharma Conference Announcements Verona Pharma (VRNA) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care Conference Date: Monday, March 3, 2025: Time: 11:10 a.m. ET / 4:10 p.m. GMT Location: Boston, MA Leerink Partners 2025 Global Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …

Gilead Sciences On February 20, 2025, Gilead Sciences (GILD) announced that the European Commission (EC) granted conditional marketing authorization to seladelpar in combination with ursodeoxycholic acid (UDCA) for the treatment of Primary Biliary Cholangitis (PBC) in adults who have inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Now approved, Seladelpar (an orphan-designated . . . This content is for …

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do not forget that Alnylam Pharmaceuticals (ALNY) is the leading RNAi Therapeutics. Keeping this in mind is important as RNAi therapeutic enables Alnylam to develop treatments together with future novel products created through gene editing, gene therapies, AI and other future technologies.  In . . . This content is for …

 What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect cancers early so they can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, state-of-the-art machine learning, software, and automation to detect and identify multiple deadly . . . This content is for paid subscribers. Please …